Ukongezwa kwonyango isicwangciso esicatshungulwa njengendlela yokuphucula iimeko zokukhupha iimpawu ze-OCD xa unyanga izigulana nge-OCD. Ukongezwa kwonyango kubandakanya ukusetyenziswa kwezidakamizwa, kunokuba ube neyeza elilodwa le-OCD, ukuze kubekho umphumo ophezulu. Amanyathelo okunyusa amaxabiso angasebenza ngokukodwa kubantu abangaphenduliyo kwiyeza eziqhelekileyo ze-OCD.
Kutheni Kuthuthukiswa Kwonyango?
Ukuba unayo i- OCD , unokwazi ukuba iindlela ezahlukeneyo zonyango ziyafumaneka. Nangona kunjalo, usenokuba nolwazi ukuba akubona bonke abantu abasabela kule mpiliso. Nangona ukwethulwa kwe -serotonin reuptake inhibitors (i-SSRIs) njengeLuvox (iFluvoxamine), i-Prozac (i-Fluoxetine), i-Paxil (i-Paroxetine) kunye ne-Zoloft (i-Sertraline), kunye ne-tricyclic antidepressants ezifana ne-Anafranil (i-Clomipramine) ibe yinyathelo elikhulu phambili unyango lwe-OCD, ama-40% ukuya kuma-60% abantu abayi kuphendula ngokwaneleyo kula mayeza. Njengoko kwezinye iindawo zonyango, iingqondo zempilo ngoku zihlola ukuba unyango lwe-OCD olunokudibanisa amayeza, kunokuba lugqithise imithi enye, lunika uncedo olungakumbi, kubantu abaninzi.
Imithi ye-Antipsychotic isetyenziselwa ukunyuka kwamayeza okwangoku
Nangona i-anti-depressants yonyango olulinganayo lwe-OCD, kuye kwacetyiswa ukuba ukongeza iziyobisi ezingasetyenziswayo kwisicwangciso sonyango kunokunceda ekuphuculeni iimpawu ze-OCD.
Kutheni oku?
Okokuqala, imishanguzo ye-antipsychotic ezifana ne-Risperdal (i-Risperidone), iZyprexa (i-Olanzapine) okanye i-Seroquel (i-Quetiapine) ithintela amanqanaba e-neurotransmitter dopamine . Iingxaki ngeenkqubo ze-dopamine ziye zafakwa kwi-OCD.
Ukongezelela, abanye abantu abane-OCD banzima ukukholelwa ukuba ukunyamezela kwabo kunye / okanye ukunyanzeliswa kwabo kungenangqiqo okanye bengenangqiqo.
Ukungaphumeleli ukuqaphela ukuba ukugqithiswa kunye / okanye ukunyanzeliswa okwenziwe ingqiqo kuye kwaboniswa ukuba kuyimqobo yokufumana unyango oluqhelekileyo. Kuye kucetyiswa ukuba imishanguzo ye-antipsychotic inokusebenza ekuncedeni ukutshintsha le ndlela yokucinga.
Ngaba ukunyanga kwamayeza kusebenza?
Ngokubanzi, ubungqina bobunzululwazi obukhoyo buxhasa ngokugqithiseleyo ukusetyenziswa kwamachiza e-antipsychotic njengamachiza okunyusa amaxabiso abantu abadala abanempawu ze-OCD abangazange baphendule kwiinkqubo eziqhelekileyo zonyango.
Nangona kunjalo, kufuneka uhlale ukhumbule ukuba kukho iindidi ezibini zemithi yokulwa ne-antipsychotic, ngasinye sinemiphumo emibi. Isizukulwana sokuqala okanye "i-typical" antipsychotics inokuba nemiphumo emibi ehambelana nokunyuka okungaqhelekanga okufana ne-tardive dyskinesia, equka ukunyanzelana nokungenakulawulwa kweendawo ezahlukeneyo zomzimba kuquka nomlomo kunye nobuso. I-Tardive i-dyskinesia ngamanye amaxesha inokuhlala isigxina xa ingaqwalaselwa ngokukhawuleza.
Isizukulwana sesibini okanye "i-atypical" antipsychotics kaninzi inomngcipheko omncinci we-tardive dyskinesia, kodwa inokubangela iingxaki zokuxilonga ezifana nokufumana ubunzima kunye noshukela wegazi ophezulu kunye ne-cholesterol.
Ngenxa yoko, inzuzo yokusebenzisa imithi yokulwa ne-antipsychotic njengeqhinga lokunciphisa ukunciphisa impawu ze-OCD kufuneka libe ngaphezu kweengozi.
Ngaloo nto, iziphumo ezibi kakhulu ezingalindelekanga kwisizukulwana sesibini okanye i-antipyychotics e-atypical zenza ukuba zikhethwa kuqala njengezithunywa zonyusa.
Njengoko naluphina unyango lwezempilo, isigqibo sokongeza imishanguzo ye-antipsychotic kwisicwangciso sakho sonyango sonyango yinto ekufuneka yenziwe ngokubambisana okunamandla kunye nosapho lwakho okanye ugqirha.
Imithombo:
I-Bloch, MH, uLanderos-Weisenberger, A., uKelmendi, B., Coric, V., Bracken, MB, & Leckman, JF "Ukuphononongwa ngokuchanekileyo: ukunyuswa kwama-antipsychotic kunye neyonyango yokuphazamiseka kwengxaki yokunyanzelisa" I- Molecular Psychiatry 2006 11: 622-632.
> Skapinakis, P., Papatheodorou T., & Mavreas, V. "Ukunyuka kwe-antipsychotic ye-serotonergic antidepressants kwimeko yokunyanga-yokunyanzeliswa kwengxaki yokungathinteli unyango: I-meta-analysis of trials randomized controlled" I- European Neuropsychopharmacology 2007 17: 79-93.